Pre & Post COVID-19 Market Estimates-Global Oligonucleotide Therapeutics Market 2020-2024 | Evolving Opportunities with Alnylam Pharmaceuticals Inc. and Arrowhead Pharmaceuticals Inc. | Technavio

LONDON--(BUSINESS WIRE)--The global oligonucleotide therapeutics market is expected to grow by USD 901.18 million as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 10%.

Request challenges and opportunities that influence COVID-19 pandemic - Request free sample pages of oligonucleotide therapeutics market

Read the 120-page report with TOC on "Oligonucleotide Therapeutics Market Analysis Report by Application (Neurological disorders, Cancer, and Others), Technology (Antisense/RNAi oligonucleotides and Others), and Geography (North America, Europe, APAC, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/global-oligonucleotide-therapeutics-market-industry-analysis

The market is driven by the increasing incidence of cancer. In addition, the increased availability of approved drugs is anticipated to boost the growth of the oligonucleotide therapeutics market.

Factors such as rising pollution, sedentary lifestyles and a number of other factors have increased the prevalence of chronic diseases such as cancer, CVD, diabetes, and autoimmune diseases. For instance, in 2016, nearly 1,658,716 new cases of cancer were reported in the US. The rate of new cases of breast cancer was 124.2 per 100,000 people and about 101.4 per 100,000 people were diagnosed with prostate cancer in 2016 in the US. The increasing prevalence of various cancer types has created a strong need for novel therapeutics. Oligonucleotides have high selectivity, affinity, and stability, and thus they are widely used as molecular probes in bioanalysis and biomedicine. Therefore, the increasing incidence of cancer is one of the key drivers influencing the growth of the global oligonucleotide therapeutics market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Oligonucleotide Therapeutics Companies:

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. operates its business through a unified business segment. The company offers RNAi therapeutics. It discovers, develops, and commercializes RNAi therapeutics for genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous diseases and ocular diseases.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc. operates its business through a unified business segment. The company offers therapeutic products with the RNAi mechanism, which leverages a natural pathway of gene silencing.

Biogen Inc.

Biogen Inc. operates its business through a unified business segment. The company offers Antisense oligonucleotide for the potential treatment of amyotrophic lateral sclerosis in adults with a confirmed superoxide dismutase 1 mutation.

Dynavax Technologies Corp.

Dynavax Technologies Corp. operates its business through a unified business segment. The company offers CpG oligonucleotides. It is a proprietary synthetic oligonucleotide, that mimics the activity of microbial DNA and selectively activate TLR9 receptor.

GlaxoSmithKline Plc

GlaxoSmithKline Plc operates its business through segments such as Pharmaceuticals, Vaccines, and Consumer Healthcare. The company offers HBV antisense oligonucleotide. It is a therapeutic antisense oligonucleotide used for the treatment of chronic hepatitis B virus infection.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Oligonucleotide Therapeutics Market Application Outlook (Revenue, USD Million, 2020-2024)

• Neurological disorders
• Cancer
• Others

Oligonucleotide Therapeutics Market Technology Outlook (Revenue, USD Million, 2020-2024)

• Antisense/RNAi oligonucleotides
• Others

Oligonucleotide Therapeutics Market Regional Outlook (Revenue, USD Million, 2020-2024)

• North America
• Europe
• APAC
• South America
• MEA

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare Include:

Global Oligonucleotide Synthesis Market – Global oligonucleotide synthesis market by end-users (pharmaceutical and biotechnology companies, research and academic institutes, diagnostic laboratories, and hospitals) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.